"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.
about
Paradoxical activity of beta-lactam antibiotics against Proteus vulgaris in experimental infection in miceDose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsOptimal drug synergy in antimicrobial treatmentsWhat preclinical data are needed to justify once-daily therapy?Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in miceEvaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection modelQuinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection modelsIn vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coliInfluence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae.Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.Continuous infusion of beta-lactam antibioticsSingle-dose antibiotic therapy: what has the past taught us?Once-a-day beta-lactam antibiotic administration.Bacterial endocarditis, Bacteriological aspectsSetting and revising antibacterial susceptibility breakpoints.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Continuous beta-lactam infusion in critically ill patients: the clinical evidencePharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.Pharmacokinetic determinants of penicillin cure of gonococcal urethritis.An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?Pharmacokinetics and pharmacodynamics of antimicrobials.In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Drug level monitoring in paediatric practice.Immediate outcomes of bacterial meningitis in childhood may benefit from slow initial β-lactam infusion and oral paracetamol.Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro modelKill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacinPharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro.Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits.
P2860
Q24679399-B13AE4E3-F7C4-4A9B-8902-BBB5813D1952Q26853629-9A622653-7A89-48E2-8861-BC79CE420FDEQ28474170-C97759D2-00DB-4818-99F3-6EC167A167D3Q30899947-B1D36E71-0E1B-4AEF-9057-8C95408563FFQ33731667-B8A872BE-DE68-4478-BAA7-C412BECD2730Q33770046-7F9F3949-0772-4EAE-8236-20AD2C6BE5A9Q33983119-02520DD2-C44D-41EB-BA1C-DF1FB2364F30Q34151060-708B557F-C33B-40FA-B665-399B5E7E62FFQ34301541-5D8598C9-7D13-4BD8-9F90-ACF93F1CAD90Q35140423-C1A7D455-43E0-4D9F-9C3B-77E0B40B5B1DQ35547159-1D06F05F-0DD7-4384-8C7C-0469E7B29061Q35566354-A1798713-D881-4D07-AEEE-DBA94E39A716Q35646823-68B7E283-4841-4840-BB8A-E6746A8C8B57Q35653815-89E9B1B3-6BFC-4694-9ED6-84B46CBC1F8BQ35656806-9C41652C-4E83-4DC0-B197-510F69ABCF71Q35661686-5B6C0742-2CC6-4B25-94A4-994292D826FEQ35661698-74E607CA-D3EE-4F6D-988C-B471BA878157Q35796725-3A94B623-500B-4756-A58A-304D55518AC7Q35913176-F1993390-AE51-4CAB-86EB-7CEC0D2D301EQ36083619-7075B633-9E09-49C1-BD8C-EA990873BA92Q36242447-4F4DD94D-43A2-4ADA-AA0D-1C1766F4B7CFQ36329228-CA2A4006-E734-4875-B404-D5873CF31FF7Q36439179-F5C83394-0EC5-4763-8431-10FBD873F178Q36480191-55A780B3-5025-4E5E-B53A-32C65703529AQ36667925-15BAC5AB-FCCB-419D-9F81-A681802D9133Q36854798-FEA8B007-24E8-414A-9A4A-1CF727DEB982Q37392734-7E342D2F-5CE2-4B49-AF41-66611BB631F8Q37625071-D16B5187-45D0-4E4F-A906-8DC0F1F41FE8Q38093135-F189B597-4D19-40B3-BB20-3452ED46C681Q38626980-25BBCE26-A250-4684-A5C5-2D6C73615C6AQ38664871-5C162222-F1F1-4F1B-93AF-4B8A994FA25AQ38896040-E846E236-9599-4C5B-848F-CD71F7D5E5B1Q38914642-4B0DEBEF-4A1A-41B7-A798-2679E82B606DQ39696732-3FCAFD69-ED67-4E55-BD56-A7E73B8B5D50Q39829105-82B23494-3550-47CD-B398-270A8D4826BDQ39833928-9FB4E9B8-EDDA-4ADF-9B92-80F6747D9E8AQ39865745-E330FDC1-B9DA-4809-A94F-CA80AA0A10E4Q39881775-C7F2AE6D-708E-4789-8065-18FEA3218165Q40087367-EA6D4846-D4BB-47BE-85B3-A0F82BA410F5Q40283340-D8484E4D-DA50-4871-AD41-A98B5C586F00
P2860
"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.
description
1953 nî lūn-bûn
@nan
1953年の論文
@ja
1953年学术文章
@wuu
1953年学术文章
@zh
1953年学术文章
@zh-cn
1953年学术文章
@zh-hans
1953年学术文章
@zh-my
1953年学术文章
@zh-sg
1953年學術文章
@yue
1953年學術文章
@zh-hant
name
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@en
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@nl
type
label
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@en
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@nl
prefLabel
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@en
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@nl
P2093
P1476
"Continuous" vs. "discontinuou ...... tions on therapeutic efficacy.
@en
P2093
P304
P356
10.1056/NEJM195303192481201
P407
P577
1953-03-01T00:00:00Z